Venmax Drugs & Pharmaceuticals Ltd Valuation
VENMAX · Healthcare · Current price ₹16.65
Is Venmax Drugs & Pharmaceuticals Ltd undervalued?
DocStoX estimates the fair value of Venmax Drugs & Pharmaceuticals Ltd at ₹9 per share, versus the current market price of ₹17. That puts the stock about -43.5% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is high.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹10), Relative P/E (₹9), Graham floor (₹8). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹8 (bear) to ₹9 (base) to ₹11 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Valuation multiples
Venmax Drugs & Pharmaceuticals Ltd trades at a P/E of 79.7x and a P/B of 1.4x, with a dividend yield of 0.0%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
Understand the ratios
More on Venmax Drugs & Pharmaceuticals Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.